Citius Pharmaceuticals Stock Set to Reverse Split on Tuesday, November 26th (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are set to reverse split on the morning of Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 25th.

Citius Pharmaceuticals Stock Performance

Shares of NASDAQ:CTXR opened at $0.13 on Friday. The stock’s 50-day moving average is $0.40 and its 200-day moving average is $0.58. The company has a market cap of $24.18 million, a P/E ratio of -0.56 and a beta of 1.66. Citius Pharmaceuticals has a 52-week low of $0.11 and a 52-week high of $1.07.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Hedge Funds Weigh In On Citius Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new stake in Citius Pharmaceuticals in the 2nd quarter valued at $29,000. BNP Paribas Financial Markets increased its stake in Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after acquiring an additional 32,686 shares during the period. XTX Topco Ltd acquired a new position in shares of Citius Pharmaceuticals in the 3rd quarter worth approximately $47,000. Miller Investment Management LP lifted its position in shares of Citius Pharmaceuticals by 99.3% during the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after buying an additional 49,640 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Citius Pharmaceuticals in the 3rd quarter valued at $50,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.